Results 21 to 30 of about 1,175 (153)

ERM Inhibition Confers Ferroptosis Resistance through ROS-Induced NRF2 Signaling. [PDF]

Adv Sci (Weinh)
ERM inhibition disrupts ERM‐actin interactions, elevating ROS and triggering KEAP1 degradation, which stabilizes and activates NRF2. Nuclear NRF2 induces cytoprotective genes, notably HMOX1, enhancing redox buffering and suppressing lipid peroxidation to resist erastin‐induced ferroptosis.
Qiao M, Zhou L, Zhou M, Fang Y, Mai H, Cao L, Xu K, Sang Y, Chen M, Huang J, Huang P, Yan Z, Wang C, Dai Z, Huang D, He R, Pang L, Guo Y, Chew TG, Huang J.   +19 more
europepmc   +2 more sources

Targeting tumor glycolysis metabolism in oral squamous cell carcinoma cells by brusatol

Pharmacological Research - Modern Chinese Medicine, 2022
Brusatol is a natural quassinoid terpenoid that shows a potential therapeutic use in treating various ailments. Recently, brusatol was shown to have anti-tumor activity and ameliorating chemoresistance or enhancing chemotherapeutic drug efficacy in vitro
Guilian Zhang, Yanlin Wu, Suhong Chen, Ying Su, Panpan Yin, Jie Fu, Xinyan Zhang   +6 more
doaj   +1 more source

Brusatol inhibits proliferation, migration, and invasion of nonsmall cell lung cancer PC-9 cells

World Journal of Traditional Chinese Medicine, 2023
Objective: The purpose of this study was to investigate the inhibitory effect of brusatol, a nigakilactone extracted from Brucea javanica, on lung cancer for development of therapeutic drugs.
Lu-Ming Yang, Wen-Min Zhou, Qiao-Ru Guo, Xin-Yue Fan, Dong-Yu Huang, Xiao-Fei Sun, Jie Yuan, Hua Yu, Hu-Biao Chen, Jian-Ye Zhang   +9 more
doaj   +1 more source

Antitumor Effect of Brusatol in Acute Lymphoblastic Leukemia Models Is Triggered by Reactive Oxygen Species Accumulation

Biomedicines, 2022
Acute lymphoblastic leukemia (ALL) is one of the most common hematological malignancies at pediatric ages and is characterized by different chromosomal rearrangements and genetic abnormalities involved in the differentiation and proliferation of lymphoid
Joana Jorge, Nisa Magalhães, Raquel Alves, Beatriz Lapa, Ana Cristina Gonçalves, Ana Bela Sarmento-Ribeiro   +5 more
doaj   +1 more source

Targeting NRF2 Sensitizes Esophageal Adenocarcinoma Cells to Cisplatin through Induction of Ferroptosis and Apoptosis

Antioxidants, 2022
Esophageal adenocarcinoma (EAC), the predominant type of esophageal cancer in the United States, develops through Barrett’s esophagus (BE)-dysplasia-carcinoma cascade. Gastroesophageal reflux disease, where acidic bile salts refluxate into the esophagus,
Farah Ballout, Heng Lu, Zheng Chen, Tianling Hu, Lei Chen, Mary Kay Washington, Wael El-Rifai, Dunfa Peng   +7 more
doaj   +1 more source

Brusatol overcomes chemoresistance through inhibition of protein translation [PDF]

Molecular Carcinogenesis, 2017
The NRF2 pathway activates a cell survival response when cells are exposed to xenobiotics or are under oxidative stress. Therapeutic activation of NRF2 can also be used prior to insult as a means of disease prevention. However, prolonged expression of NRF2 has been shown to protect cancer cells by inducing the metabolism and efflux of chemotherapeutics,
Bryan, Harder, Wang, Tian, James J, La Clair, Aik-Choon, Tan, Aikseng, Ooi, Eli, Chapman, Donna D, Zhang   +6 more
openaire   +2 more sources

Brusatol From Suppresses Arsenic Trioxide-Induced PD-L1 Upregulation Through Inhibition of NRF2 in Leukemia Cells

Natural Product Communications, 2022
Overexpression of programed death-ligand 1 (PD-L1) is associated with poor prognosis in leukemia. Moreover, antitumor pharmaceuticals have been shown to induce immunoresistance, leading to reduced efficacy.
Shunji Zhang, Meijuan Sui, Zhuo Zhang, Yanhua Su   +3 more
doaj   +1 more source

Targeted Inhibition of Anti-Inflammatory Regulator Nrf2 Results in Breast Cancer Retardation In Vitro and In Vivo

Biomedicines, 2021
Nuclear factor erythroid-2 related factor-2 (Nrf2) is an oxidative stress-response transcriptional activator that promotes carcinogenesis through metabolic reprogramming, tumor promoting inflammation, and therapeutic resistance. However, the extension of
Venugopal R. Bovilla, Mahadevaswamy G. Kuruburu, Vidya G. Bettada, Jayashree Krishnamurthy, Olga A. Sukocheva, Rajesh K. Thimmulappa, Nanjunda Swamy Shivananju, Janardhan P. Balakrishna, SubbaRao V. Madhunapantula   +8 more
doaj   +1 more source

Repositioning Brusatol as a Transmission Blocker of Malaria Parasites. [PDF]

ACS Infect Dis
Currently, primaquine is the only malaria transmission-blocking drug recommended by the WHO. Recent efforts have highlighted the importance of discovering new agents that regulate malarial transmission, with particular interest in agents that can be administered in a single low dose, ideally with a discrete and Plasmodium-selective mechanism of action.
Cox A, Krishnankutty N, Shave S, Howick VM, Auer M, La Clair JJ, Philip N.   +6 more
europepmc   +5 more sources

Brusatol modulates diverse cancer hallmarks and signaling pathways as a potential cancer therapeutic

Acta Materia Medica, 2022
Cancer is a consequence of uncontrolled cell proliferation that is associated with cell-cycle disruption. It is a multifactorial disease that depends on the modulation of numerous oncogenic signaling pathways and targets. Although a battle against cancer
Song-Bin Guo, Wei-Juan Huang, Xiao-Peng Tian   +2 more
doaj   +1 more source